fruquintinib

Org: Department of Oncology, Liwan District People's Hospital of Guangzhou, Guangzhou, China, Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,

Abstract

Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.

Org: Medical Oncology Service. Hospital G. U. Gregorio Marañón. IiSGM. Universidad Complutense, Allina Health Cancer Institute, Poitiers University Hospital and University of Poitiers, HUTCHMED Limited,

Abstract

Phase Ib/II trial of hepatic arterial infusion chemotherapy in combination with fruquintinib for refractory unresectable colorectal cancer liver metastases.

Org: Department of Interventional Therapy,

Abstract

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multicenter, single-arm, phase 2 trial.

Org: The Central Hospital of Xiao Gan, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, Xiang Yang Central Hospital, Hubei University of Art and Science,

Abstract

Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study.

Org: Department of Orthopaedics, Zhejiang University, Hangzhou, China, Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China, Peking University People’s Hospital, Beijing, China,

Abstract

Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.

Org: Department of Abdominal and Pelvic Medical Oncology, The First People's Hospital of Tianmen City, Affiliated Hospital of Hubei Technology College, Tianmen, China,

Abstract

Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial.

Org: The First Affiliated Hospital of Suzhou University, Suzhou, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of Soochow University,

Abstract

Efficacy and safety of fruquintinib across different subgroups of patients with previously treated metastatic colorectal cancer: A meta-analysis.

Org: Universidade Federal da Bahia,

Abstract

Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.

Org: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Liaoning Cancer Hospital, Liaoning, China, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, Department of Gynecologic Oncology, affiliated Cancer Hospital of Chonqing University, Chongqing, China, Beijing Obstetrics and Gynecolgoy Hospital, Capital Medical University, Beijing, China,

Abstract

A propensity score–matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: Real-world data.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,

Abstract

Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort.

Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, Huangshi Central Hospital of Hubei Province, Huangshi, China, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Hubei Cancer Hosp, Wuhan, China, Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China,

Abstract

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study.

Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Union Hospital Medical College,

Abstract

Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE).

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,

Abstract

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.

Org: Veneto Institute of Oncology IOV-IRCCS Padua, Asklepios Tumorzentrum Hamburg, Takeda Pharma Vertrieb GmbH & Co. KG, HUTCHMED International Inc., University Hospitals Gasthuisberg / Leuven & KULeuven,

Clinical trial

Single-arm, Multicentre Real-world Observational Study of TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2024-06-01

Abstract

Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.

Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,

Abstract

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

Org: University of Texas MD Anderson Cancer Center, Veneto Institute of Oncology IOV - IRCCS, Hospital Universitario 12 de Octubre, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.

Org: The University of Arizona, Tucson, AZ, University of Arizona Cancer Center, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

Org: Renmin Hospital of Wuhan University, Xiantao First People’s Hospital, Jianghan Oilfield General Hospital, The Central Hospital of Xiao Gan, Xiang Yang Central Hospital,

Abstract

Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric adenocarcinoma (FRUTINEOGA): A multicenter, phase II study.

Org: Guangxi Medical University Cancer Hospital, Guangxi Medical University Affiliated Tumor Hospital, Wuming Hospital of Guangxi Medical University,

Abstract

Fruquintinib plus sintilimab in patients with either treatment-naive or previously first line treated metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multicenter, single-arm phase 2 study.

Org: Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Hospital, Peking University First Hospital, Chongqing University Cancer Hospital, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China,

Abstract

Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.

Org: Eli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Lilly China Drug Development and Medical Affairs Center,

Abstract

Fruquintinib versus fruquintinib combined with PD-1 inhibitors for metastatic colorectal cancer: Real-world data.

Org: State Key Laboratory of Oncogenesis and Related Genes, Department of Oncology, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Oncology, Renji Hospital, Shanghai Jiaotong University Medicine School,

Abstract

Association of neutrophil/lymphocyte ratio and IFN-γ with clinical response and survival in patients with MSS/pMMR mCRC treated with anti-PD-1 and VEGF inhibitors.

Org: Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai Tenth People's Hospital Chongming Branch, Department of Oncology, Shanghai Tenth People's Hospital,

Abstract

A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.

Org: Tongji University Shanghai East Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences,

Abstract

Phase II study of fruquintinib as second or further-line therapy for patients with advanced biliary tract cancer.

Org: West China Hospital, Sichuan University, Chengdu, Sichuan, China, Department of Abdominal Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliate Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China, West China School of Clinical Medicine,

Abstract

Cost-utility analyses of later-line treatments for metastatic colorectal cancer (mCRC) by network meta-analysis (NMA) approach: Conventional constant hazard ratio vs novel survival curves methodologies.

Org: University of Arizona, University of Arizona Cancer Center, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,

Abstract

A phase II study of fruquintinib in the first- (1L) or second-line (2L) treatment of unresectable metastatic soft tissue sarcoma.

Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University,

Abstract

Comparative efficacy of later-line therapies for metastatic colorectal cancer (mCRC) using novel methods for patient survival data reconstruction and network meta-analysis (NMA) of survival curves.

Org: University of Arizona of Pharmacy, Department of Pharmacy Practice and Science, University of Arizona Cancer Center, The University of Arizona, Tucson, AZ, University of Arizona,

Abstract

A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.

Org: Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Provincial Hospital of Chinese Medicine Breast Center, Guangdong Provincial People's Hospital,

Product

Fruquintinib, Nivolumab, Sintilimab, Oxaliplatin, Teysuno, Capecitabine

Product

fruquintinib + gemcitabine + nab-paclitaxel

Product

SABR + fruquintinib + tislelizumab

Product

fruquintinib plus paclitaxel

Product

Fruquintinib, Toripalimab, Short-course radiotherapy

Product

Fruquintinib + Paclitaxel

Product

fruquintinib + sintilimab + platinum-based chemotherapy